SIMILAR PATTERNS OF AMINO ACIDS FOR 5L2I_A_LQQA900_1

List of similar pattern of amino acids derived from ASSAM search

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click link on the last column to view superposed patterns of amino acids in NGL viewer)
(Note that only 3-12 residue patterns can be used for ASSAM searches)

Filter list by:

	Hit	Macromolecule/ Organism	Pfam	Res.	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1h4l	CELL DIVISION PROTEIN KINASE 5 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 18 ALA A 31 VAL A 64 PHE A 80 ASP A 86 LEU A 133 ALA A 143	None	0.77A	5l2iA-1h4lA: 14.2	5l2iA-1h4lA: 45.28
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1k9a	CARBOXYL-TERMINAL SRC KINASE (Rattus norvegicus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	ILE A 201 GLY A 202 VAL A 209 ALA A 220 VAL A 249 LEU A 321	None	0.72A	5l2iA-1k9aA: 7.2	5l2iA-1k9aA: 23.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1luf	MUSCLE-SPECIFIC TYROSINE KINASE RECEPTOR MUSK (Rattus norvegicus)	PF07714 (Pkinase_Tyr)	8	ILE A 580 GLY A 581 VAL A 588 ALA A 606 VAL A 638 PHE A 654 ASP A 661 LEU A 731	None	0.71A	5l2iA-1lufA: 7.0	5l2iA-1lufA: 26.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1luf	MUSCLE-SPECIFIC TYROSINE KINASE RECEPTOR MUSK (Rattus norvegicus)	PF07714 (Pkinase_Tyr)	8	ILE A 580 VAL A 588 ALA A 606 VAL A 638 PHE A 654 ASP A 661 LEU A 731 ALA A 741	None	0.66A	5l2iA-1lufA: 7.0	5l2iA-1lufA: 26.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1q8y	SR PROTEIN KINASE (Saccharomyces cerevisiae)	PF00069 (Pkinase)	6	GLY A 165 VAL A 172 ALA A 185 PHE A 246 LEU A 301 ALA A 549	ADP A 810 (-3.3A) ADP A 810 (-4.1A) ADP A 810 (-3.3A) None ADP A 810 (-4.7A) None	0.72A	5l2iA-1q8yA: 10.0	5l2iA-1q8yA: 27.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	GLY A 617 VAL A 624 ALA A 642 VAL A 675 PHE A 691 ASP A 698 LEU A 818	None	0.60A	5l2iA-1rjbA: 6.6	5l2iA-1rjbA: 25.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1snx	TYROSINE-PROTEIN KINASE ITK/TSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	GLY A 370 VAL A 377 ALA A 389 VAL A 419 PHE A 435 LEU A 489	None	0.50A	5l2iA-1snxA: 8.4	5l2iA-1snxA: 27.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1t46	HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	GLY A 596 VAL A 603 ALA A 621 VAL A 654 ASP A 677 LEU A 799	None STI A 3 ( 4.6A) STI A 3 (-3.5A) STI A 3 (-4.3A) None STI A 3 (-4.4A)	0.53A	5l2iA-1t46A: 6.6	5l2iA-1t46A: 26.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1v0b	CELL DIVISION CONTROL PROTEIN 2 HOMOLOG (Plasmodium falciparum)	PF00069 (Pkinase)	8	GLY A 11 VAL A 18 ALA A 30 VAL A 63 PHE A 79 ASP A 85 LEU A 132 ALA A 142	None	0.56A	5l2iA-1v0bA: 17.2	5l2iA-1v0bA: 45.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1v0b	CELL DIVISION CONTROL PROTEIN 2 HOMOLOG (Plasmodium falciparum)	PF00069 (Pkinase)	7	ILE A 10 GLY A 11 VAL A 18 ALA A 30 VAL A 63 PHE A 79 ASP A 85	None	0.99A	5l2iA-1v0bA: 17.2	5l2iA-1v0bA: 45.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2dq7	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	GLY X 18 VAL X 25 ALA X 37 VAL X 67 LEU X 137 ALA X 147	STU X 902 ( 3.7A) STU X 902 ( 4.8A) STU X 902 (-3.1A) None STU X 902 (-4.4A) STU X 902 ( 4.1A)	0.46A	5l2iA-2dq7X: 7.1	5l2iA-2dq7X: 26.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2dq7	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL X 25 ALA X 37 VAL X 67 LEU X 137 ALA X 147 ASP X 148	STU X 902 ( 4.8A) STU X 902 (-3.1A) None STU X 902 (-4.4A) STU X 902 ( 4.1A) STU X 902 (-3.6A)	0.63A	5l2iA-2dq7X: 7.1	5l2iA-2dq7X: 26.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2eu9	DUAL SPECIFICITY PROTEIN KINASE CLK3 (Homo sapiens)	PF00069 (Pkinase)	7	GLY A 163 VAL A 170 ALA A 184 VAL A 220 PHE A 236 LEU A 290 ALA A 319	None	0.83A	5l2iA-2eu9A: 11.4	5l2iA-2eu9A: 30.47
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2h8h	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	GLY A 274 VAL A 281 ALA A 293 VAL A 323 LEU A 393 ALA A 403	H8H A 534 ( 3.8A) H8H A 534 (-4.4A) H8H A 534 (-3.2A) None H8H A 534 (-4.5A) H8H A 534 ( 4.0A)	0.72A	5l2iA-2h8hA: 6.9	5l2iA-2h8hA: 20.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2hz0	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	GLY A 249 VAL A 256 ALA A 269 VAL A 299 LEU A 370 ALA A 380	None GIN A 600 ( 4.7A) GIN A 600 (-3.1A) GIN A 600 (-4.6A) GIN A 600 (-4.7A) GIN A 600 (-3.1A)	0.47A	5l2iA-2hz0A: 5.9	5l2iA-2hz0A: 25.95
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2jgz	CELL DIVISION PROTEIN KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	7	ALA A 31 VAL A 64 PHE A 80 ASP A 86 LEU A 134 ALA A 144 ASP A 145	None	0.69A	5l2iA-2jgzA: 18.9	5l2iA-2jgzA: 48.69
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2jgz	CELL DIVISION PROTEIN KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	8	GLY A 11 VAL A 18 ALA A 31 VAL A 64 PHE A 80 ASP A 86 LEU A 134 ALA A 144	None	0.66A	5l2iA-2jgzA: 18.9	5l2iA-2jgzA: 48.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2jkm	FOCAL ADHESION KINASE 1 (Gallus gallus)	PF07714 (Pkinase_Tyr)	6	ILE A 428 GLY A 429 VAL A 436 ALA A 452 VAL A 484 LEU A 553	BII A1687 (-3.8A) BII A1687 ( 3.8A) BII A1687 ( 4.7A) BII A1687 (-3.5A) None BII A1687 (-4.2A)	0.73A	5l2iA-2jkmA: 10.3	5l2iA-2jkmA: 26.58
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ogv	MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	GLY A 589 VAL A 596 ALA A 614 VAL A 647 ASP A 670 LEU A 785	None	0.56A	5l2iA-2ogvA: 8.1	5l2iA-2ogvA: 23.74
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2v55	RHO-ASSOCIATED PROTEIN KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	7	GLY A 83 VAL A 90 ALA A 103 VAL A 137 ASP A 160 LEU A 205 ALA A 215	ANP A1480 ( 4.3A) None ANP A1480 ( 3.9A) ANP A1480 (-4.7A) ANP A1480 (-4.0A) ANP A1480 ( 4.7A) ANP A1480 ( 4.1A)	0.65A	5l2iA-2v55A: 7.5	5l2iA-2v55A: 26.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2vuw	SERINE/THREONINE-PRO TEIN KINASE HASPIN (Homo sapiens)	PF12330 (Haspin_kinase)	7	ILE A 490 GLY A 491 VAL A 498 ALA A 509 PHE A 605 ASP A 611 LEU A 656	None 5ID A1800 (-3.5A) 5ID A1800 ( 4.5A) 5ID A1800 (-3.4A) 5ID A1800 (-4.1A) 5ID A1800 (-3.6A) 5ID A1800 (-4.5A)	0.85A	5l2iA-2vuwA: 15.5	5l2iA-2vuwA: 24.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2w4o	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE TYPE IV (Homo sapiens)	PF00069 (Pkinase)	6	GLY A 53 VAL A 60 ALA A 73 LEU A 171 ALA A 184 ASP A 185	DKI A1338 (-3.3A) DKI A1338 (-4.2A) DKI A1338 ( 3.7A) DKI A1338 (-4.9A) DKI A1338 (-3.1A) DKI A1338 (-3.8A)	0.68A	5l2iA-2w4oA: 7.2	5l2iA-2w4oA: 27.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2w9f	CELL DIVISION PROTEIN KINASE 4 (Homo sapiens)	PF00069 (Pkinase)	9	GLY B 13 VAL B 20 ALA B 33 VAL B 72 PHE B 93 ASP B 99 THR B 102 LEU B 147 ALA B 157	None	0.63A	5l2iA-2w9fB: 12.1	5l2iA-2w9fB: 69.11
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2w9f	CELL DIVISION PROTEIN KINASE 4 (Homo sapiens)	PF00069 (Pkinase)	9	ILE B 12 GLY B 13 VAL B 20 ALA B 33 VAL B 72 PHE B 93 THR B 102 LEU B 147 ALA B 157	None	0.77A	5l2iA-2w9fB: 12.1	5l2iA-2w9fB: 69.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2z7r	RIBOSOMAL PROTEIN S6 KINASE ALPHA-1 (Homo sapiens)	PF00069 (Pkinase)	7	GLY A 69 VAL A 76 ALA A 92 VAL A 125 ASP A 148 THR A 151 LEU A 194	STU A 1 (-3.3A) None STU A 1 (-3.3A) None STU A 1 (-3.8A) None STU A 1 (-4.6A)	0.63A	5l2iA-2z7rA: 8.7	5l2iA-2z7rA: 29.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2z7r	RIBOSOMAL PROTEIN S6 KINASE ALPHA-1 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 76 ALA A 92 VAL A 125 ASP A 148 THR A 151 LEU A 194 ASP A 205	None STU A 1 (-3.3A) None STU A 1 (-3.8A) None STU A 1 (-4.6A) STU A 1 ( 3.8A)	0.74A	5l2iA-2z7rA: 8.7	5l2iA-2z7rA: 29.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3bhh	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE TYPE II BETA CHAIN (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 28 ALA A 41 VAL A 74 PHE A 90 LEU A 143 ALA A 156 ASP A 157	5CP A 600 ( 4.4A) 5CP A 600 (-3.6A) 5CP A 600 ( 4.7A) 5CP A 600 ( 4.3A) 5CP A 600 (-4.4A) 5CP A 600 ( 3.9A) 5CP A 600 (-3.5A)	0.63A	5l2iA-3bhhA: 7.6	5l2iA-3bhhA: 30.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3c0i	PERIPHERAL PLASMA MEMBRANE PROTEIN CASK (Homo sapiens)	PF00069 (Pkinase)	7	ILE A 18 GLY A 19 VAL A 26 ALA A 39 VAL A 75 PHE A 91 LEU A 148	3AM A 338 (-4.5A) None 3AM A 338 ( 4.1A) 3AM A 338 (-3.3A) None 3AM A 338 (-3.6A) 3AM A 338 (-4.7A)	0.68A	5l2iA-3c0iA: 7.7	5l2iA-3c0iA: 26.49
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3d7u	TYROSINE-PROTEIN KINASE CSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ILE A 201 GLY A 202 VAL A 209 ALA A 220 VAL A 249 LEU A 321	None	0.72A	5l2iA-3d7uA: 7.2	5l2iA-3d7uA: 25.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3dak	SERINE/THREONINE-PRO TEIN KINASE OSR1 (Homo sapiens)	PF00069 (Pkinase)	7	ILE A 23 GLY A 24 VAL A 31 ALA A 44 VAL A 76 LEU A 153 ALA A 163	ANP A 1 (-4.2A) ANP A 1 (-3.3A) ANP A 1 (-4.5A) ANP A 1 ( 3.9A) None None MG A 296 ( 3.9A)	0.73A	5l2iA-3dakA: 5.5	5l2iA-3dakA: 26.88
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3f2a	PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE PIM-1 (Homo sapiens)	PF00069 (Pkinase)	6	GLY A 45 VAL A 52 ALA A 65 ASP A 128 LEU A 174 ASP A 186	985 A 1 ( 3.9A) 985 A 1 (-4.5A) 985 A 1 (-3.5A) 985 A 1 (-4.7A) 985 A 1 (-4.8A) 985 A 1 ( 4.0A)	0.66A	5l2iA-3f2aA: 22.9	5l2iA-3f2aA: 26.61
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3iec	SERINE/THREONINE-PRO TEIN KINASE MARK2 (Homo sapiens)	PF00069 (Pkinase) PF00627 (UBA)	6	GLY A 60 VAL A 67 ALA A 80 VAL A 113 LEU A 182 ALA A 192	None	0.70A	5l2iA-3iecA: 7.6	5l2iA-3iecA: 27.14
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3mdy	BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (Homo sapiens)	PF07714 (Pkinase_Tyr) PF08515 (TGF_beta_GS)	6	GLY A 211 VAL A 218 ALA A 229 LEU A 339 ALA A 349 ASP A 350	LDN A 1 ( 4.7A) LDN A 1 ( 4.8A) LDN A 1 (-3.6A) LDN A 1 (-4.5A) LDN A 1 ( 3.8A) LDN A 1 (-3.9A)	0.70A	5l2iA-3mdyA: 6.3	5l2iA-3mdyA: 27.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3mi9	CELL DIVISION PROTEIN KINASE 9 (Homo sapiens)	PF00069 (Pkinase)	7	ALA A 46 VAL A 79 PHE A 103 ASP A 109 LEU A 156 ALA A 166 ASP A 167	None	0.82A	5l2iA-3mi9A: 12.6	5l2iA-3mi9A: 36.87
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3mi9	CELL DIVISION PROTEIN KINASE 9 (Homo sapiens)	PF00069 (Pkinase)	8	ILE A 25 VAL A 33 ALA A 46 VAL A 79 PHE A 103 ASP A 109 LEU A 156 ALA A 166	None	0.78A	5l2iA-3mi9A: 12.6	5l2iA-3mi9A: 36.87
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3mtl	CELL DIVISION PROTEIN KINASE 16 (Homo sapiens)	PF00069 (Pkinase)	8	GLY A 172 VAL A 179 ALA A 192 VAL A 224 PHE A 240 ASP A 246 LEU A 293 ALA A 303	FEF A 668 ( 4.2A) FEF A 668 (-4.9A) FEF A 668 (-3.3A) FEF A 668 (-4.7A) FEF A 668 ( 4.3A) FEF A 668 ( 4.3A) FEF A 668 (-4.2A) FEF A 668 ( 4.0A)	0.56A	5l2iA-3mtlA: 18.0	5l2iA-3mtlA: 39.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3niz	RHODANESE FAMILY PROTEIN (Cryptosporidium parvum)	PF00069 (Pkinase)	7	GLY A 30 VAL A 37 ALA A 49 VAL A 82 ASP A 104 LEU A 151 ALA A 161	ADP A 314 (-3.3A) ADP A 314 (-4.0A) ADP A 314 (-3.5A) None ADP A 314 (-4.1A) ADP A 314 (-4.6A) None	0.81A	5l2iA-3nizA: 13.6	5l2iA-3nizA: 45.12
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3nyo	G PROTEIN-COUPLED RECEPTOR KINASE 6 (Homo sapiens)	PF00069 (Pkinase) PF00615 (RGS)	6	GLY A 193 VAL A 200 ALA A 213 VAL A 247 ASP A 270 LEU A 318	AMP A 577 ( 3.7A) AMP A 577 (-4.3A) AMP A 577 (-3.4A) None AMP A 577 (-3.6A) AMP A 577 (-4.8A)	0.58A	5l2iA-3nyoA: 7.8	5l2iA-3nyoA: 21.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3oz6	MITOGEN-ACTIVATED PROTEIN KINASE 1, SERINE/THREONINE PROTEIN KINASE (Cryptosporidium parvum)	PF00069 (Pkinase)	6	ALA A 38 VAL A 72 PHE A 90 ASP A 96 LEU A 141 ALA A 151	None	0.73A	5l2iA-3oz6A: 13.9	5l2iA-3oz6A: 30.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3ppz	SERINE/THREONINE-PRO TEIN KINASE CTR1 (Arabidopsis thaliana)	PF07714 (Pkinase_Tyr)	6	ILE A 557 GLY A 558 VAL A 565 ALA A 576 VAL A 609 LEU A 683	STU A 1 (-4.1A) STU A 1 (-3.2A) STU A 1 (-4.9A) STU A 1 (-3.3A) None STU A 1 (-4.3A)	0.68A	5l2iA-3ppzA: 6.5	5l2iA-3ppzA: 26.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3qfv	CDC42BPB PROTEIN (Homo sapiens)	PF00069 (Pkinase)	8	GLY A 83 VAL A 90 ALA A 103 ASP A 160 THR A 163 LEU A 207 ALA A 217 ASP A 218	NM7 A 416 (-3.0A) NM7 A 416 (-3.7A) NM7 A 416 ( 3.7A) None None NM7 A 416 ( 4.2A) NM7 A 416 ( 4.5A) EDO A 417 (-3.7A)	0.66A	5l2iA-3qfvA: 6.5	5l2iA-3qfvA: 25.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3txo	PROTEIN KINASE C ETA TYPE (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	6	GLY A 362 VAL A 369 ALA A 382 ASP A 440 LEU A 486 ALA A 496	07U A 1 ( 4.2A) 07U A 1 (-4.8A) 07U A 1 (-3.3A) 07U A 1 (-3.9A) 07U A 1 (-4.3A) 07U A 1 ( 4.0A)	0.46A	5l2iA-3txoA: 20.1	5l2iA-3txoA: 27.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3zdu	CYCLIN-DEPENDENT KINASE-LIKE 3 (Homo sapiens)	PF00069 (Pkinase)	7	GLY A 11 TYR A 15 VAL A 18 ALA A 31 VAL A 63 PHE A 79 LEU A 132	38R A 350 ( 3.9A) None 38R A 350 ( 4.8A) 38R A 350 (-3.4A) 38R A 350 ( 4.9A) 38R A 350 (-4.1A) 38R A 350 (-4.3A)	0.79A	5l2iA-3zduA: 12.4	5l2iA-3zduA: 33.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	PF00069 (Pkinase)	7	ILE A 10 GLY A 11 VAL A 18 ALA A 31 VAL A 64 PHE A 80 LEU A 133	D15 A 500 (-4.2A) D15 A 500 (-3.8A) D15 A 500 (-4.6A) D15 A 500 (-3.4A) None D15 A 500 ( 4.3A) D15 A 500 (-4.5A)	0.64A	5l2iA-4aguA: 16.4	5l2iA-4aguA: 35.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4at3	BDNF/NT-3 GROWTH FACTORS RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	GLY A 561 VAL A 568 ALA A 586 VAL A 617 PHE A 633 ASP A 640 LEU A 699	LTI A1839 ( 4.3A) None LTI A1839 (-3.3A) None LTI A1839 (-3.5A) None LTI A1839 (-4.2A)	1.20A	5l2iA-4at3A: 6.7	5l2iA-4at3A: 27.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4aw2	SERINE/THREONINE-PRO TEIN KINASE MRCK ALPHA (Rattus norvegicus)	PF00069 (Pkinase) PF00433 (Pkinase_C)	8	GLY A 84 VAL A 91 ALA A 104 ASP A 161 THR A 164 LEU A 208 ALA A 218 ASP A 219	None None EDO A1420 (-3.4A) None None EDO A1420 ( 4.8A) None None	0.74A	5l2iA-4aw2A: 7.1	5l2iA-4aw2A: 25.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4aw2	SERINE/THREONINE-PRO TEIN KINASE MRCK ALPHA (Rattus norvegicus)	PF00069 (Pkinase) PF00433 (Pkinase_C)	7	ILE A 83 GLY A 84 VAL A 91 ALA A 104 ASP A 161 THR A 164 LEU A 208	None None None EDO A1420 (-3.4A) None None EDO A1420 ( 4.8A)	0.90A	5l2iA-4aw2A: 7.1	5l2iA-4aw2A: 25.73
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4bbm	CYCLIN-DEPENDENT KINASE-LIKE 2 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 18 ALA A 31 VAL A 64 PHE A 80 LEU A 133 ASP A 144	None TC0 A 500 (-3.5A) TC0 A 500 (-4.7A) TC0 A 500 (-3.4A) TC0 A 500 (-4.3A) TC0 A 500 (-4.8A)	0.58A	5l2iA-4bbmA: 13.2	5l2iA-4bbmA: 33.62
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4bgq	CYCLIN-DEPENDENT KINASE-LIKE 5 (Homo sapiens)	PF00069 (Pkinase)	7	GLY A 20 TYR A 24 VAL A 27 ALA A 40 VAL A 73 PHE A 89 LEU A 142	None 38R A1000 (-3.6A) 38R A1000 ( 4.8A) 38R A1000 (-3.4A) None 38R A1000 ( 3.8A) 38R A1000 ( 4.5A)	0.85A	5l2iA-4bgqA: 16.7	5l2iA-4bgqA: 35.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4crs	SERINE/THREONINE-PRO TEIN KINASE N2 (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	6	VAL A 671 ALA A 684 VAL A 721 ASP A 744 LEU A 789 ALA A 799	AGS A1985 (-4.6A) AGS A1985 (-3.5A) None AGS A1985 (-4.0A) AGS A1985 (-4.8A) AGS A1985 ( 4.5A)	0.45A	5l2iA-4crsA: 8.0	5l2iA-4crsA: 26.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4e93	TYROSINE-PROTEIN KINASE FES/FPS (Homo sapiens)	PF00017 (SH2) PF07714 (Pkinase_Tyr)	6	ALA A 588 VAL A 620 ASP A 643 THR A 646 LEU A 690 ASP A 701	GUI A 901 (-3.4A) None GUI A 901 ( 4.8A) GUI A 901 ( 3.8A) GUI A 901 (-4.3A) GUI A 901 ( 4.1A)	0.65A	5l2iA-4e93A: 7.6	5l2iA-4e93A: 22.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4e93	TYROSINE-PROTEIN KINASE FES/FPS (Homo sapiens)	PF00017 (SH2) PF07714 (Pkinase_Tyr)	8	ILE A 567 GLY A 568 VAL A 575 ALA A 588 VAL A 620 ASP A 643 THR A 646 LEU A 690	GUI A 901 (-4.0A) GUI A 901 ( 4.3A) GUI A 901 (-4.5A) GUI A 901 (-3.4A) None GUI A 901 ( 4.8A) GUI A 901 ( 3.8A) GUI A 901 (-4.3A)	1.03A	5l2iA-4e93A: 7.6	5l2iA-4e93A: 22.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4eut	SERINE/THREONINE-PRO TEIN KINASE TBK1 (Homo sapiens)	PF00069 (Pkinase)	6	GLY A 16 VAL A 23 ALA A 36 VAL A 68 THR A 96 ASP A 157	BX7 A 401 ( 3.7A) BX7 A 401 (-4.4A) BX7 A 401 (-3.4A) None BX7 A 401 ( 4.7A) BX7 A 401 ( 3.7A)	0.74A	5l2iA-4eutA: 20.4	5l2iA-4eutA: 26.89
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ez5	CYCLIN-DEPENDENT KINASE 6 (Homo sapiens)	PF00069 (Pkinase)	9	GLY A 20 VAL A 27 VAL A 77 PHE A 98 ASP A 104 THR A 106 LEU A 152 ALA A 162 ASP A 163	None None 0RS A 900 (-4.4A) 0RS A 900 (-4.5A) 0RS A 900 (-4.2A) None 0RS A 900 (-4.3A) 0RS A 900 (-3.6A) 0RS A 900 (-3.6A)	1.32A	5l2iA-4ez5A: 24.2	5l2iA-4ez5A: 100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ez5	CYCLIN-DEPENDENT KINASE 6 (Homo sapiens)	PF00069 (Pkinase)	11	ILE A 19 GLY A 20 VAL A 27 ALA A 41 VAL A 77 PHE A 98 ASP A 104 THR A 107 LEU A 152 ALA A 162 ASP A 163	0RS A 900 (-4.1A) None None 0RS A 900 ( 3.7A) 0RS A 900 (-4.4A) 0RS A 900 (-4.5A) 0RS A 900 (-4.2A) 0RS A 900 (-4.2A) 0RS A 900 (-4.3A) 0RS A 900 (-3.6A) 0RS A 900 (-3.6A)	0.55A	5l2iA-4ez5A: 24.2	5l2iA-4ez5A: 100.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4f0i	HIGH AFFINITY NERVE GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	GLY A 516 VAL A 523 ALA A 541 VAL A 572 PHE A 588 ASP A 595 LEU A 656	None	0.83A	5l2iA-4f0iA: 6.5	5l2iA-4f0iA: 27.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4fr4	SERINE/THREONINE-PRO TEIN KINASE 32A (Homo sapiens)	PF00069 (Pkinase)	7	ILE A 29 GLY A 30 VAL A 37 ALA A 50 VAL A 84 ASP A 107 LEU A 153	STU A 401 (-4.1A) STU A 401 (-3.3A) STU A 401 ( 4.9A) STU A 401 (-3.2A) None STU A 401 (-3.3A) STU A 401 (-4.7A)	0.74A	5l2iA-4fr4A: 6.9	5l2iA-4fr4A: 24.49
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4hvi	TYROSINE-PROTEIN KINASE JAK3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	GLY A 829 VAL A 836 ALA A 853 VAL A 884 LEU A 956 ALA A 966	19S A1201 (-3.7A) 19S A1201 (-4.4A) 19S A1201 (-3.3A) None 19S A1201 (-4.5A) 19S A1201 ( 4.1A)	0.56A	5l2iA-4hviA: 22.9	5l2iA-4hviA: 26.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4otd	SERINE/THREONINE-PRO TEIN KINASE N1 (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	7	GLY A 628 VAL A 635 ALA A 648 VAL A 685 ASP A 708 LEU A 753 ALA A 763	None	0.64A	5l2iA-4otdA: 7.3	5l2iA-4otdA: 27.42
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4otd	SERINE/THREONINE-PRO TEIN KINASE N1 (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	7	VAL A 635 ALA A 648 VAL A 685 ASP A 708 LEU A 753 ALA A 763 ASP A 764	None	0.89A	5l2iA-4otdA: 7.3	5l2iA-4otdA: 27.42
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4q9z	HUMAN PROTEIN KINASE C THETA (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	6	GLY A 387 VAL A 394 ALA A 407 ASP A 465 LEU A 511 ALA A 521	PZW A 801 ( 3.8A) PZW A 801 (-4.6A) PZW A 801 (-3.5A) None PZW A 801 (-4.8A) PZW A 801 ( 4.6A)	0.72A	5l2iA-4q9zA: 7.4	5l2iA-4q9zA: 28.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4qtb	MITOGEN-ACTIVATED PROTEIN KINASE 3 (Homo sapiens)	PF00069 (Pkinase)	7	ILE A 48 GLY A 49 TYR A 53 VAL A 56 ALA A 69 ASP A 128 LEU A 173	38Z A 418 ( 4.4A) None 38Z A 418 (-3.5A) None 38Z A 418 (-3.4A) EDO A 413 (-2.9A) 38Z A 418 (-4.4A)	0.75A	5l2iA-4qtbA: 14.0	5l2iA-4qtbA: 34.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4rew	5'-AMP-ACTIVATED PROTEIN KINASE CATALYTIC SUBUNIT ALPHA-1 (Homo sapiens)	PF00069 (Pkinase) PF16579 (AdenylateSensor)	6	GLY A 25 VAL A 32 ALA A 45 LEU A 148 ALA A 158 ASP A 159	STU A 601 (-3.5A) STU A 601 ( 4.8A) STU A 601 (-3.2A) STU A 601 (-4.2A) STU A 601 ( 3.8A) STU A 601 (-3.7A)	0.72A	5l2iA-4rewA: 8.0	5l2iA-4rewA: 20.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4rt7	RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	GLY A 617 VAL A 624 ALA A 642 VAL A 675 PHE A 691 ASP A 698 LEU A 818	None None P30 A1001 (-3.4A) None P30 A1001 (-3.7A) None P30 A1001 (-4.6A)	0.51A	5l2iA-4rt7A: 6.7	5l2iA-4rt7A: 23.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4wbo	RHODOPSIN KINASE (Bos taurus)	PF00069 (Pkinase) PF00615 (RGS)	6	GLY A 194 VAL A 201 ALA A 214 VAL A 248 ASP A 271 LEU A 321	None None ANW A 601 (-3.4A) None None ANW A 601 (-4.9A)	0.67A	5l2iA-4wboA: 22.2	5l2iA-4wboA: 19.89
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4xuf	RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	GLY A 617 VAL A 624 ALA A 642 VAL A 675 PHE A 691 ASP A 698 LEU A 818	None P30 A1001 ( 4.8A) P30 A1001 (-3.5A) None P30 A1001 ( 4.3A) None P30 A1001 (-4.3A)	0.54A	5l2iA-4xufA: 6.9	5l2iA-4xufA: 28.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4yc6	CYCLIN-DEPENDENT KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	7	GLY A 13 ALA A 31 VAL A 64 ASP A 86 LEU A 135 ALA A 145 ASP A 146	None	1.34A	5l2iA-4yc6A: 14.6	5l2iA-4yc6A: 45.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4yc6	CYCLIN-DEPENDENT KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 18 ALA A 31 VAL A 64 PHE A 80 ASP A 86 LEU A 135 ALA A 145	None	0.68A	5l2iA-4yc6A: 14.6	5l2iA-4yc6A: 45.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4yff	SERINE/THREONINE-PRO TEIN KINASE TNNI3K (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	GLY A 470 VAL A 477 ALA A 488 LEU A 595 ALA A 605 ASP A 606	4CV A 801 ( 3.9A) None 4CV A 801 (-3.5A) 4CV A 801 (-4.4A) 4CV A 801 ( 3.9A) 4CV A 801 (-3.5A)	0.51A	5l2iA-4yffA: 21.4	5l2iA-4yffA: 26.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4yff	SERINE/THREONINE-PRO TEIN KINASE TNNI3K (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ILE A 469 GLY A 470 VAL A 477 ALA A 488 LEU A 595 ALA A 605	4CV A 801 (-4.3A) 4CV A 801 ( 3.9A) None 4CV A 801 (-3.5A) 4CV A 801 (-4.4A) 4CV A 801 ( 3.9A)	0.69A	5l2iA-4yffA: 21.4	5l2iA-4yffA: 26.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4yhj	G PROTEIN-COUPLED RECEPTOR KINASE 4 (Homo sapiens)	PF00069 (Pkinase) PF00615 (RGS)	6	GLY A 194 VAL A 201 ALA A 214 VAL A 248 ASP A 271 LEU A 319	AN2 A 601 (-3.4A) AN2 A 601 (-4.0A) AN2 A 601 (-3.6A) None None None	0.71A	5l2iA-4yhjA: 9.2	5l2iA-4yhjA: 21.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ylj	DUAL SPECIFICITY TYROSINE-PHOSPHORYLA TION-REGULATED KINASE 1A (Homo sapiens)	PF00069 (Pkinase)	7	ILE A 165 GLY A 166 VAL A 173 ALA A 186 VAL A 222 PHE A 238 LEU A 294	4E1 A 505 ( 4.6A) 4E1 A 505 (-3.5A) 4E1 A 505 (-4.5A) 4E1 A 505 (-3.5A) None 4E1 A 505 (-4.2A) None	0.74A	5l2iA-4yljA: 12.8	5l2iA-4yljA: 29.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ci7	SERINE/THREONINE-PRO TEIN KINASE ULK1 (Homo sapiens)	PF00069 (Pkinase)	7	GLY A 23 VAL A 30 ALA A 44 VAL A 76 ASP A 99 ALA A 164 ASP A 165	51W A 401 (-3.3A) 51W A 401 ( 4.3A) 51W A 401 (-3.4A) None 51W A 401 (-3.8A) None GOL A 404 (-3.2A)	0.82A	5l2iA-5ci7A: 8.1	5l2iA-5ci7A: 29.23
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ci7	SERINE/THREONINE-PRO TEIN KINASE ULK1 (Homo sapiens)	PF00069 (Pkinase)	7	GLY A 23 VAL A 30 ALA A 44 VAL A 76 ASP A 99 LEU A 145 ALA A 164	51W A 401 (-3.3A) 51W A 401 ( 4.3A) 51W A 401 (-3.4A) None 51W A 401 (-3.8A) 51W A 401 (-4.5A) None	0.61A	5l2iA-5ci7A: 8.1	5l2iA-5ci7A: 29.23
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5dbx	STE20/SPS1-RELATED PROLINE-ALANINE-RICH PROTEIN KINASE (Mus musculus)	PF00069 (Pkinase)	6	ILE A 81 GLY A 82 VAL A 89 ALA A 102 VAL A 134 LEU A 211	ANP A 401 ( 4.1A) ANP A 401 ( 3.9A) ANP A 401 (-4.0A) ANP A 401 ( 4.0A) None None	0.67A	5l2iA-5dbxA: 5.2	5l2iA-5dbxA: 27.27
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5es1	MAP/MICROTUBULE AFFINITY-REGULATING KINASE 4 (Homo sapiens)	PF00069 (Pkinase) PF00627 (UBA)	6	GLY A 63 VAL A 70 ALA A 83 VAL A 116 LEU A 185 ALA A 195	5RC A4000 ( 4.3A) 5RC A4000 (-4.6A) 5RC A4000 (-3.6A) None None 5RC A4000 ( 3.9A)	0.65A	5l2iA-5es1A: 8.0	5l2iA-5es1A: 27.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5grn	PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	GLY A 600 VAL A 607 ALA A 625 VAL A 658 ASP A 681 LEU A 825	None 748 A1001 ( 4.7A) 748 A1001 (-3.7A) 748 A1001 ( 4.8A) None 748 A1001 (-4.3A)	0.55A	5l2iA-5grnA: 22.4	5l2iA-5grnA: 26.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5gza	PROTEIN O-MANNOSE KINASE (Danio rerio)	PF07714 (Pkinase_Tyr)	6	GLY A 86 VAL A 93 ALA A 104 VAL A 133 THR A 157 LEU A 214	ADP A 401 (-3.6A) ADP A 401 (-4.4A) ADP A 401 (-3.2A) None None ADP A 401 (-4.4A)	0.52A	5l2iA-5gzaA: 15.7	5l2iA-5gzaA: 23.24
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5hu3	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE TYPE II ALPHA CHAIN (Drosophila melanogaster)	PF00069 (Pkinase)	7	GLY A 21 VAL A 28 ALA A 41 VAL A 74 PHE A 90 LEU A 143 ALA A 156	ADP A 301 (-3.6A) ADP A 301 (-3.7A) ADP A 301 (-3.5A) None None ADP A 301 (-4.7A) ADP A 301 ( 4.8A)	0.69A	5l2iA-5hu3A: 7.9	5l2iA-5hu3A: 31.56
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5idn	CYCLIN-DEPENDENT KINASE 8 (Homo sapiens)	PF00069 (Pkinase)	6	GLY A 28 VAL A 35 ALA A 50 ASP A 103 LEU A 158 ALA A 172	6A7 A 401 (-3.6A) 6A7 A 401 ( 4.5A) 6A7 A 401 (-3.3A) 6A7 A 401 ( 4.9A) 6A7 A 401 (-4.8A) 6A7 A 401 ( 4.1A)	0.63A	5l2iA-5idnA: 14.3	5l2iA-5idnA: 32.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5idn	CYCLIN-DEPENDENT KINASE 8 (Homo sapiens)	PF00069 (Pkinase)	6	GLY A 28 VAL A 35 ALA A 50 PHE A 97 LEU A 158 ALA A 172	6A7 A 401 (-3.6A) 6A7 A 401 ( 4.5A) 6A7 A 401 (-3.3A) 6A7 A 401 (-3.8A) 6A7 A 401 (-4.8A) 6A7 A 401 ( 4.1A)	0.68A	5l2iA-5idnA: 14.3	5l2iA-5idnA: 32.80
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ig1	CAMK/CAMK2 PROTEIN KINASE (Salpingoeca rosetta)	PF00069 (Pkinase)	7	ILE A 24 GLY A 25 VAL A 32 ALA A 45 VAL A 78 PHE A 94 LEU A 147	None	0.84A	5l2iA-5ig1A: 7.8	5l2iA-5ig1A: 28.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5iso	5'-AMP-ACTIVATED PROTEIN KINASE CATALYTIC SUBUNIT ALPHA-2 (Homo sapiens)	PF00069 (Pkinase) PF16579 (AdenylateSensor)	6	GLY A 23 VAL A 30 ALA A 43 LEU A 146 ALA A 156 ASP A 157	STU A 601 (-3.4A) STU A 601 (-4.8A) STU A 601 (-3.3A) STU A 601 (-4.5A) STU A 601 (-3.5A) STU A 601 (-3.5A)	0.60A	5l2iA-5isoA: 7.8	5l2iA-5isoA: 22.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5j5t	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 3 (Homo sapiens)	PF00069 (Pkinase)	7	GLY A 23 VAL A 30 ALA A 43 VAL A 74 LEU A 143 ALA A 153 ASP A 154	None 6G2 A 901 ( 4.9A) 6G2 A 901 (-3.2A) None 6G2 A 901 (-4.7A) 6G2 A 901 ( 4.2A) 6G2 A 901 (-3.4A)	0.64A	5l2iA-5j5tA: 20.9	5l2iA-5j5tA: 26.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5jzn	SERINE/THREONINE-PRO TEIN KINASE DCLK1 (Homo sapiens)	PF00069 (Pkinase)	6	GLY A 397 VAL A 404 ALA A 417 VAL A 449 ASP A 472 LEU A 518	GUI A 701 ( 3.8A) GUI A 701 (-4.4A) GUI A 701 ( 3.9A) None None GUI A 701 (-4.4A)	0.63A	5l2iA-5jznA: 7.9	5l2iA-5jznA: 31.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5loh	SERINE/THREONINE-PRO TEIN KINASE GREATWALL,SERINE/THR EONINE-PROTEIN KINASE GREATWALL (Homo sapiens)	PF00069 (Pkinase)	6	ILE A 41 VAL A 49 ALA A 60 VAL A 94 ASP A 117 LEU A 163	STU A 901 (-4.3A) None STU A 901 (-3.3A) None STU A 901 (-4.2A) STU A 901 (-4.5A)	0.59A	5l2iA-5lohA: 8.3	5l2iA-5lohA: 27.09
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5lxd	DUAL SPECIFICITY TYROSINE-PHOSPHORYLA TION-REGULATED KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	6	ILE A 155 GLY A 156 VAL A 163 ALA A 176 PHE A 228 LEU A 282	7A7 A 501 ( 4.3A) 7A7 A 501 (-3.2A) 7A7 A 501 (-4.4A) 7A7 A 501 (-3.5A) 7A7 A 501 (-3.7A) 7A7 A 501 (-4.9A)	0.48A	5l2iA-5lxdA: 16.1	5l2iA-5lxdA: 26.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5myv	SRSF PROTEIN KINASE 2,SRSF PROTEIN KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	6	GLY A 99 VAL A 106 ALA A 119 VAL A 157 PHE A 177 LEU A 232	W4A A 716 ( 4.0A) W4A A 716 ( 4.7A) W4A A 716 ( 3.9A) DMS A 717 (-4.3A) DMS A 717 ( 3.9A) None	0.74A	5l2iA-5myvA: 14.6	5l2iA-5myvA: 26.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ncl	SERINE/THREONINE-PRO TEIN KINASE CBK1 (Saccharomyces cerevisiae)	no annotation	8	ILE A 358 GLY A 359 VAL A 366 ALA A 379 VAL A 413 ASP A 436 THR A 439 LEU A 482	ANP A 801 (-4.2A) ANP A 801 ( 4.1A) ANP A 801 (-4.7A) ANP A 801 ( 3.9A) ANP A 801 ( 4.9A) ANP A 801 (-3.4A) None ANP A 801 (-4.8A)	0.79A	5l2iA-5nclA: 21.3	5l2iA-5nclA: 16.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5u7q	RHO-ASSOCIATED PROTEIN KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	7	GLY A 99 VAL A 106 ALA A 119 VAL A 153 ASP A 176 LEU A 221 ALA A 231	None	0.55A	5l2iA-5u7qA: 7.6	5l2iA-5u7qA: 26.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5xv7	SERINE-ARGININE (SR) PROTEIN KINASE 1 (Homo sapiens)	no annotation	7	GLY A 87 VAL A 94 ALA A 107 VAL A 145 PHE A 165 LEU A 220 ALA A 496	EMH A 705 ( 3.9A) EMH A 705 ( 4.4A) EMH A 705 (-3.6A) EMH A 705 ( 4.9A) EMH A 705 (-3.6A) None EMH A 705 ( 4.0A)	0.89A	5l2iA-5xv7A: 10.9	5l2iA-5xv7A: 14.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5y86	DUAL SPECIFICITY TYROSINE-PHOSPHORYLA TION-REGULATED KINASE 3 (Homo sapiens)	no annotation	6	GLY A 216 VAL A 223 ALA A 236 PHE A 288 ASP A 294 LEU A 342	None HRM A 601 ( 4.9A) HRM A 601 (-3.5A) HRM A 601 (-3.6A) None None	0.66A	5l2iA-5y86A: 13.1	5l2iA-5y86A: 13.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6b3e	CYCLIN-DEPENDENT KINASE 12 (Homo sapiens)	no annotation	9	GLY A 734 VAL A 741 ALA A 754 VAL A 787 PHE A 813 ASP A 819 LEU A 866 ALA A 876 ASP A 877	CJM A1102 (-3.4A) None CJM A1102 (-3.1A) None CJM A1102 ( 4.4A) CJM A1102 (-4.1A) CJM A1102 (-4.4A) CJM A1102 (-3.6A) MG A1101 (-2.5A)	0.89A	5l2iA-6b3eA: 13.1	5l2iA-6b3eA: 16.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6b3e	CYCLIN-DEPENDENT KINASE 12 (Homo sapiens)	no annotation	7	ILE A 733 GLY A 734 VAL A 741 ALA A 754 PHE A 813 ASP A 819 LEU A 866	CJM A1102 (-3.4A) CJM A1102 (-3.4A) None CJM A1102 (-3.1A) CJM A1102 ( 4.4A) CJM A1102 (-4.1A) CJM A1102 (-4.4A)	0.74A	5l2iA-6b3eA: 13.1	5l2iA-6b3eA: 16.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6bql	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE KINASE 2 (Homo sapiens)	no annotation	7	GLY A 172 VAL A 179 ALA A 192 VAL A 249 PHE A 267 LEU A 319 ALA A 329	BI9 A 501 (-3.6A) BI9 A 501 ( 4.8A) BI9 A 501 (-3.3A) None BI9 A 501 ( 4.2A) BI9 A 501 (-4.7A) NH4 A 506 ( 3.7A)	0.84A	5l2iA-6bqlA: 8.0	5l2iA-6bqlA: 13.64
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6c9d	SERINE/THREONINE-PRO TEIN KINASE MARK1,SERINE/THREONI NE-PROTEIN KINASE MARK1 (Homo sapiens)	no annotation	7	ILE A 66 GLY A 67 VAL A 74 ALA A 87 VAL A 120 LEU A 189 ALA A 199	None	0.91A	5l2iA-6c9dA: 7.8	5l2iA-6c9dA: 12.99
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6ccf	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE KINASE 1 (Homo sapiens)	no annotation	7	GLY A 135 TYR A 139 VAL A 142 ALA A 155 VAL A 212 LEU A 282 ALA A 292	H1N A 501 ( 3.8A) None H1N A 501 (-4.4A) H1N A 501 (-3.4A) H1N A 501 (-4.9A) H1N A 501 (-4.8A) H1N A 501 ( 3.9A)	0.70A	5l2iA-6ccfA: 8.3	5l2iA-6ccfA: 15.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6ccf	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE KINASE 1 (Homo sapiens)	no annotation	7	GLY A 135 VAL A 142 ALA A 155 VAL A 212 PHE A 230 LEU A 282 ALA A 292	H1N A 501 ( 3.8A) H1N A 501 (-4.4A) H1N A 501 (-3.4A) H1N A 501 (-4.9A) H1N A 501 (-3.7A) H1N A 501 (-4.8A) H1N A 501 ( 3.9A)	0.63A	5l2iA-6ccfA: 8.3	5l2iA-6ccfA: 15.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6cmj	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE KINASE 2 (Homo sapiens)	no annotation	8	GLY A 172 VAL A 179 ALA A 192 VAL A 249 PHE A 267 LEU A 319 ALA A 329 ASP A 330	F6J A 501 ( 3.9A) F6J A 501 (-4.6A) F6J A 501 (-3.4A) None F6J A 501 (-3.7A) F6J A 501 (-4.5A) F6J A 501 ( 4.0A) F6J A 501 (-3.8A)	0.81A	5l2iA-6cmjA: 22.4	5l2iA-6cmjA: 11.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6fyo	DUAL SPECIFICITY PROTEIN KINASE CLK1 (Homo sapiens)	no annotation	6	GLY A 168 VAL A 175 ALA A 189 VAL A 225 PHE A 241 LEU A 295	None None EAQ A 501 (-3.6A) None EAQ A 501 (-3.5A) EAQ A 501 (-4.9A)	0.64A	5l2iA-6fyoA: 9.9	5l2iA-6fyoA: undetectable

[["5L2I_A_LQQA900_1","1h4l","Homo sapiens","CELL DIVISION PROTEIN KINASE 5","PF00069(Pkinase)",7,"VAL A  18;ALA A  31;VAL A  64;PHE A  80;ASP A  86;LEU A 133;ALA A 143","None","0.77A","5l2iA-1h4lA:14.2","5l2iA-1h4lA:45.28"],["5L2I_A_LQQA900_1","1k9a","Rattus norvegicus","CARBOXYL-TERMINAL SRC KINASE","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"ILE A 201;GLY A 202;VAL A 209;ALA A 220;VAL A 249;LEU A 321","None","0.72A","5l2iA-1k9aA:7.2","5l2iA-1k9aA:23.91"],["5L2I_A_LQQA900_1","1luf","Rattus norvegicus","MUSCLE-SPECIFIC TYROSINE KINASE RECEPTOR MUSK","PF07714(Pkinase_Tyr)",8,"ILE A 580;GLY A 581;VAL A 588;ALA A 606;VAL A 638;PHE A 654;ASP A 661;LEU A 731","None","0.71A","5l2iA-1lufA:7.0","5l2iA-1lufA:26.98"],["5L2I_A_LQQA900_1","1luf","Rattus norvegicus","MUSCLE-SPECIFIC TYROSINE KINASE RECEPTOR MUSK","PF07714(Pkinase_Tyr)",8,"ILE A 580;VAL A 588;ALA A 606;VAL A 638;PHE A 654;ASP A 661;LEU A 731;ALA A 741","None","0.66A","5l2iA-1lufA:7.0","5l2iA-1lufA:26.98"],["5L2I_A_LQQA900_1","1q8y","Saccharomyces cerevisiae","SR PROTEIN KINASE","PF00069(Pkinase)",6,"GLY A 165;VAL A 172;ALA A 185;PHE A 246;LEU A 301;ALA A 549","ADP A 810 (-3.3A);ADP A 810 (-4.1A);ADP A 810 (-3.3A);None;ADP A 810 (-4.7A);None","0.72A","5l2iA-1q8yA:10.0","5l2iA-1q8yA:27.37"],["5L2I_A_LQQA900_1","1rjb","Homo sapiens","FL CYTOKINE RECEPTOR","PF07714(Pkinase_Tyr)",7,"GLY A 617;VAL A 624;ALA A 642;VAL A 675;PHE A 691;ASP A 698;LEU A 818","None","0.60A","5l2iA-1rjbA:6.6","5l2iA-1rjbA:25.86"],["5L2I_A_LQQA900_1","1snx","Homo sapiens","TYROSINE-PROTEIN KINASE ITK\/TSK","PF07714(Pkinase_Tyr)",6,"GLY A 370;VAL A 377;ALA A 389;VAL A 419;PHE A 435;LEU A 489","None","0.50A","5l2iA-1snxA:8.4","5l2iA-1snxA:27.30"],["5L2I_A_LQQA900_1","1t46","Homo sapiens","HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG","PF07714(Pkinase_Tyr)",6,"GLY A 596;VAL A 603;ALA A 621;VAL A 654;ASP A 677;LEU A 799","None;STI A   3 ( 4.6A);STI A   3 (-3.5A);STI A   3 (-4.3A);None;STI A   3 (-4.4A)","0.53A","5l2iA-1t46A:6.6","5l2iA-1t46A:26.02"],["5L2I_A_LQQA900_1","1v0b","Plasmodium falciparum","CELL DIVISION CONTROL PROTEIN 2 HOMOLOG","PF00069(Pkinase)",8,"GLY A  11;VAL A  18;ALA A  30;VAL A  63;PHE A  79;ASP A  85;LEU A 132;ALA A 142","None","0.56A","5l2iA-1v0bA:17.2","5l2iA-1v0bA:45.31"],["5L2I_A_LQQA900_1","1v0b","Plasmodium falciparum","CELL DIVISION CONTROL PROTEIN 2 HOMOLOG","PF00069(Pkinase)",7,"ILE A  10;GLY A  11;VAL A  18;ALA A  30;VAL A  63;PHE A  79;ASP A  85","None","0.99A","5l2iA-1v0bA:17.2","5l2iA-1v0bA:45.31"],["5L2I_A_LQQA900_1","2dq7","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN","PF07714(Pkinase_Tyr)",6,"GLY X  18;VAL X  25;ALA X  37;VAL X  67;LEU X 137;ALA X 147","STU X 902 ( 3.7A);STU X 902 ( 4.8A);STU X 902 (-3.1A);None;STU X 902 (-4.4A);STU X 902 ( 4.1A)","0.46A","5l2iA-2dq7X:7.1","5l2iA-2dq7X:26.50"],["5L2I_A_LQQA900_1","2dq7","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN","PF07714(Pkinase_Tyr)",6,"VAL X  25;ALA X  37;VAL X  67;LEU X 137;ALA X 147;ASP X 148","STU X 902 ( 4.8A);STU X 902 (-3.1A);None;STU X 902 (-4.4A);STU X 902 ( 4.1A);STU X 902 (-3.6A)","0.63A","5l2iA-2dq7X:7.1","5l2iA-2dq7X:26.50"],["5L2I_A_LQQA900_1","2eu9","Homo sapiens","DUAL SPECIFICITY PROTEIN KINASE CLK3","PF00069(Pkinase)",7,"GLY A 163;VAL A 170;ALA A 184;VAL A 220;PHE A 236;LEU A 290;ALA A 319","None","0.83A","5l2iA-2eu9A:11.4","5l2iA-2eu9A:30.47"],["5L2I_A_LQQA900_1","2h8h","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"GLY A 274;VAL A 281;ALA A 293;VAL A 323;LEU A 393;ALA A 403","H8H A 534 ( 3.8A);H8H A 534 (-4.4A);H8H A 534 (-3.2A);None;H8H A 534 (-4.5A);H8H A 534 ( 4.0A)","0.72A","5l2iA-2h8hA:6.9","5l2iA-2h8hA:20.07"],["5L2I_A_LQQA900_1","2hz0","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF07714(Pkinase_Tyr)",6,"GLY A 249;VAL A 256;ALA A 269;VAL A 299;LEU A 370;ALA A 380","None;GIN A 600 ( 4.7A);GIN A 600 (-3.1A);GIN A 600 (-4.6A);GIN A 600 (-4.7A);GIN A 600 (-3.1A)","0.47A","5l2iA-2hz0A:5.9","5l2iA-2hz0A:25.95"],["5L2I_A_LQQA900_1","2jgz","Homo sapiens","CELL DIVISION PROTEIN KINASE 2","PF00069(Pkinase)",7,"ALA A  31;VAL A  64;PHE A  80;ASP A  86;LEU A 134;ALA A 144;ASP A 145","None","0.69A","5l2iA-2jgzA:18.9","5l2iA-2jgzA:48.69"],["5L2I_A_LQQA900_1","2jgz","Homo sapiens","CELL DIVISION PROTEIN KINASE 2","PF00069(Pkinase)",8,"GLY A  11;VAL A  18;ALA A  31;VAL A  64;PHE A  80;ASP A  86;LEU A 134;ALA A 144","None","0.66A","5l2iA-2jgzA:18.9","5l2iA-2jgzA:48.69"],["5L2I_A_LQQA900_1","2jkm","Gallus gallus","FOCAL ADHESION KINASE 1","PF07714(Pkinase_Tyr)",6,"ILE A 428;GLY A 429;VAL A 436;ALA A 452;VAL A 484;LEU A 553","BII A1687 (-3.8A);BII A1687 ( 3.8A);BII A1687 ( 4.7A);BII A1687 (-3.5A);None;BII A1687 (-4.2A)","0.73A","5l2iA-2jkmA:10.3","5l2iA-2jkmA:26.58"],["5L2I_A_LQQA900_1","2ogv","Homo sapiens","MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR","PF07714(Pkinase_Tyr)",6,"GLY A 589;VAL A 596;ALA A 614;VAL A 647;ASP A 670;LEU A 785","None","0.56A","5l2iA-2ogvA:8.1","5l2iA-2ogvA:23.74"],["5L2I_A_LQQA900_1","2v55","Homo sapiens","RHO-ASSOCIATED PROTEIN KINASE 1","PF00069(Pkinase)",7,"GLY A  83;VAL A  90;ALA A 103;VAL A 137;ASP A 160;LEU A 205;ALA A 215","ANP A1480 ( 4.3A);None;ANP A1480 ( 3.9A);ANP A1480 (-4.7A);ANP A1480 (-4.0A);ANP A1480 ( 4.7A);ANP A1480 ( 4.1A)","0.65A","5l2iA-2v55A:7.5","5l2iA-2v55A:26.20"],["5L2I_A_LQQA900_1","2vuw","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE HASPIN","PF12330(Haspin_kinase)",7,"ILE A 490;GLY A 491;VAL A 498;ALA A 509;PHE A 605;ASP A 611;LEU A 656","None;5ID A1800 (-3.5A);5ID A1800 ( 4.5A);5ID A1800 (-3.4A);5ID A1800 (-4.1A);5ID A1800 (-3.6A);5ID A1800 (-4.5A)","0.85A","5l2iA-2vuwA:15.5","5l2iA-2vuwA:24.73"],["5L2I_A_LQQA900_1","2w4o","Homo sapiens","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE TYPE IV","PF00069(Pkinase)",6,"GLY A  53;VAL A  60;ALA A  73;LEU A 171;ALA A 184;ASP A 185","DKI A1338 (-3.3A);DKI A1338 (-4.2A);DKI A1338 ( 3.7A);DKI A1338 (-4.9A);DKI A1338 (-3.1A);DKI A1338 (-3.8A)","0.68A","5l2iA-2w4oA:7.2","5l2iA-2w4oA:27.75"],["5L2I_A_LQQA900_1","2w9f","Homo sapiens","CELL DIVISION PROTEIN KINASE 4","PF00069(Pkinase)",9,"GLY B  13;VAL B  20;ALA B  33;VAL B  72;PHE B  93;ASP B  99;THR B 102;LEU B 147;ALA B 157","None","0.63A","5l2iA-2w9fB:12.1","5l2iA-2w9fB:69.11"],["5L2I_A_LQQA900_1","2w9f","Homo sapiens","CELL DIVISION PROTEIN KINASE 4","PF00069(Pkinase)",9,"ILE B  12;GLY B  13;VAL B  20;ALA B  33;VAL B  72;PHE B  93;THR B 102;LEU B 147;ALA B 157","None","0.77A","5l2iA-2w9fB:12.1","5l2iA-2w9fB:69.11"],["5L2I_A_LQQA900_1","2z7r","Homo sapiens","RIBOSOMAL PROTEIN S6 KINASE ALPHA-1","PF00069(Pkinase)",7,"GLY A  69;VAL A  76;ALA A  92;VAL A 125;ASP A 148;THR A 151;LEU A 194","STU A   1 (-3.3A);None;STU A   1 (-3.3A);None;STU A   1 (-3.8A);None;STU A   1 (-4.6A)","0.63A","5l2iA-2z7rA:8.7","5l2iA-2z7rA:29.55"],["5L2I_A_LQQA900_1","2z7r","Homo sapiens","RIBOSOMAL PROTEIN S6 KINASE ALPHA-1","PF00069(Pkinase)",7,"VAL A  76;ALA A  92;VAL A 125;ASP A 148;THR A 151;LEU A 194;ASP A 205","None;STU A   1 (-3.3A);None;STU A   1 (-3.8A);None;STU A   1 (-4.6A);STU A   1 ( 3.8A)","0.74A","5l2iA-2z7rA:8.7","5l2iA-2z7rA:29.55"],["5L2I_A_LQQA900_1","3bhh","Homo sapiens","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE TYPE II BETA CHAIN","PF00069(Pkinase)",7,"VAL A  28;ALA A  41;VAL A  74;PHE A  90;LEU A 143;ALA A 156;ASP A 157","5CP A 600 ( 4.4A);5CP A 600 (-3.6A);5CP A 600 ( 4.7A);5CP A 600 ( 4.3A);5CP A 600 (-4.4A);5CP A 600 ( 3.9A);5CP A 600 (-3.5A)","0.63A","5l2iA-3bhhA:7.6","5l2iA-3bhhA:30.68"],["5L2I_A_LQQA900_1","3c0i","Homo sapiens","PERIPHERAL PLASMA MEMBRANE PROTEIN CASK","PF00069(Pkinase)",7,"ILE A  18;GLY A  19;VAL A  26;ALA A  39;VAL A  75;PHE A  91;LEU A 148","3AM A 338 (-4.5A);None;3AM A 338 ( 4.1A);3AM A 338 (-3.3A);None;3AM A 338 (-3.6A);3AM A 338 (-4.7A)","0.68A","5l2iA-3c0iA:7.7","5l2iA-3c0iA:26.49"],["5L2I_A_LQQA900_1","3d7u","Homo sapiens","TYROSINE-PROTEIN KINASE CSK","PF07714(Pkinase_Tyr)",6,"ILE A 201;GLY A 202;VAL A 209;ALA A 220;VAL A 249;LEU A 321","None","0.72A","5l2iA-3d7uA:7.2","5l2iA-3d7uA:25.86"],["5L2I_A_LQQA900_1","3dak","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE OSR1","PF00069(Pkinase)",7,"ILE A  23;GLY A  24;VAL A  31;ALA A  44;VAL A  76;LEU A 153;ALA A 163","ANP A   1 (-4.2A);ANP A   1 (-3.3A);ANP A   1 (-4.5A);ANP A   1 ( 3.9A);None;None; MG A 296 ( 3.9A)","0.73A","5l2iA-3dakA:5.5","5l2iA-3dakA:26.88"],["5L2I_A_LQQA900_1","3f2a","Homo sapiens","PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE PIM-1","PF00069(Pkinase)",6,"GLY A  45;VAL A  52;ALA A  65;ASP A 128;LEU A 174;ASP A 186","985 A   1 ( 3.9A);985 A   1 (-4.5A);985 A   1 (-3.5A);985 A   1 (-4.7A);985 A   1 (-4.8A);985 A   1 ( 4.0A)","0.66A","5l2iA-3f2aA:22.9","5l2iA-3f2aA:26.61"],["5L2I_A_LQQA900_1","3iec","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE MARK2","PF00069(Pkinase);PF00627(UBA)",6,"GLY A  60;VAL A  67;ALA A  80;VAL A 113;LEU A 182;ALA A 192","None","0.70A","5l2iA-3iecA:7.6","5l2iA-3iecA:27.14"],["5L2I_A_LQQA900_1","3mdy","Homo sapiens","BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B","PF07714(Pkinase_Tyr);PF08515(TGF_beta_GS)",6,"GLY A 211;VAL A 218;ALA A 229;LEU A 339;ALA A 349;ASP A 350","LDN A   1 ( 4.7A);LDN A   1 ( 4.8A);LDN A   1 (-3.6A);LDN A   1 (-4.5A);LDN A   1 ( 3.8A);LDN A   1 (-3.9A)","0.70A","5l2iA-3mdyA:6.3","5l2iA-3mdyA:27.75"],["5L2I_A_LQQA900_1","3mi9","Homo sapiens","CELL DIVISION PROTEIN KINASE 9","PF00069(Pkinase)",7,"ALA A  46;VAL A  79;PHE A 103;ASP A 109;LEU A 156;ALA A 166;ASP A 167","None","0.82A","5l2iA-3mi9A:12.6","5l2iA-3mi9A:36.87"],["5L2I_A_LQQA900_1","3mi9","Homo sapiens","CELL DIVISION PROTEIN KINASE 9","PF00069(Pkinase)",8,"ILE A  25;VAL A  33;ALA A  46;VAL A  79;PHE A 103;ASP A 109;LEU A 156;ALA A 166","None","0.78A","5l2iA-3mi9A:12.6","5l2iA-3mi9A:36.87"],["5L2I_A_LQQA900_1","3mtl","Homo sapiens","CELL DIVISION PROTEIN KINASE 16","PF00069(Pkinase)",8,"GLY A 172;VAL A 179;ALA A 192;VAL A 224;PHE A 240;ASP A 246;LEU A 293;ALA A 303","FEF A 668 ( 4.2A);FEF A 668 (-4.9A);FEF A 668 (-3.3A);FEF A 668 (-4.7A);FEF A 668 ( 4.3A);FEF A 668 ( 4.3A);FEF A 668 (-4.2A);FEF A 668 ( 4.0A)","0.56A","5l2iA-3mtlA:18.0","5l2iA-3mtlA:39.60"],["5L2I_A_LQQA900_1","3niz","Cryptosporidium parvum","RHODANESE FAMILY PROTEIN","PF00069(Pkinase)",7,"GLY A  30;VAL A  37;ALA A  49;VAL A  82;ASP A 104;LEU A 151;ALA A 161","ADP A 314 (-3.3A);ADP A 314 (-4.0A);ADP A 314 (-3.5A);None;ADP A 314 (-4.1A);ADP A 314 (-4.6A);None","0.81A","5l2iA-3nizA:13.6","5l2iA-3nizA:45.12"],["5L2I_A_LQQA900_1","3nyo","Homo sapiens","G PROTEIN-COUPLED RECEPTOR KINASE 6","PF00069(Pkinase);PF00615(RGS)",6,"GLY A 193;VAL A 200;ALA A 213;VAL A 247;ASP A 270;LEU A 318","AMP A 577 ( 3.7A);AMP A 577 (-4.3A);AMP A 577 (-3.4A);None;AMP A 577 (-3.6A);AMP A 577 (-4.8A)","0.58A","5l2iA-3nyoA:7.8","5l2iA-3nyoA:21.31"],["5L2I_A_LQQA900_1","3oz6","Cryptosporidium parvum","MITOGEN-ACTIVATED PROTEIN KINASE 1, SERINE\/THREONINE PROTEIN KINASE","PF00069(Pkinase)",6,"ALA A  38;VAL A  72;PHE A  90;ASP A  96;LEU A 141;ALA A 151","None","0.73A","5l2iA-3oz6A:13.9","5l2iA-3oz6A:30.67"],["5L2I_A_LQQA900_1","3ppz","Arabidopsis thaliana","SERINE\/THREONINE-PROTEIN KINASE CTR1","PF07714(Pkinase_Tyr)",6,"ILE A 557;GLY A 558;VAL A 565;ALA A 576;VAL A 609;LEU A 683","STU A   1 (-4.1A);STU A   1 (-3.2A);STU A   1 (-4.9A);STU A   1 (-3.3A);None;STU A   1 (-4.3A)","0.68A","5l2iA-3ppzA:6.5","5l2iA-3ppzA:26.05"],["5L2I_A_LQQA900_1","3qfv","Homo sapiens","CDC42BPB PROTEIN","PF00069(Pkinase)",8,"GLY A  83;VAL A  90;ALA A 103;ASP A 160;THR A 163;LEU A 207;ALA A 217;ASP A 218","NM7 A 416 (-3.0A);NM7 A 416 (-3.7A);NM7 A 416 ( 3.7A);None;None;NM7 A 416 ( 4.2A);NM7 A 416 ( 4.5A);EDO A 417 (-3.7A)","0.66A","5l2iA-3qfvA:6.5","5l2iA-3qfvA:25.98"],["5L2I_A_LQQA900_1","3txo","Homo sapiens","PROTEIN KINASE C ETA TYPE","PF00069(Pkinase);PF00433(Pkinase_C)",6,"GLY A 362;VAL A 369;ALA A 382;ASP A 440;LEU A 486;ALA A 496","07U A   1 ( 4.2A);07U A   1 (-4.8A);07U A   1 (-3.3A);07U A   1 (-3.9A);07U A   1 (-4.3A);07U A   1 ( 4.0A)","0.46A","5l2iA-3txoA:20.1","5l2iA-3txoA:27.27"],["5L2I_A_LQQA900_1","3zdu","Homo sapiens","CYCLIN-DEPENDENT KINASE-LIKE 3","PF00069(Pkinase)",7,"GLY A  11;TYR A  15;VAL A  18;ALA A  31;VAL A  63;PHE A  79;LEU A 132","38R A 350 ( 3.9A);None;38R A 350 ( 4.8A);38R A 350 (-3.4A);38R A 350 ( 4.9A);38R A 350 (-4.1A);38R A 350 (-4.3A)","0.79A","5l2iA-3zduA:12.4","5l2iA-3zduA:33.99"],["5L2I_A_LQQA900_1","4agu","Homo sapiens","CYCLIN-DEPENDENT KINASE-LIKE 1","PF00069(Pkinase)",7,"ILE A  10;GLY A  11;VAL A  18;ALA A  31;VAL A  64;PHE A  80;LEU A 133","D15 A 500 (-4.2A);D15 A 500 (-3.8A);D15 A 500 (-4.6A);D15 A 500 (-3.4A);None;D15 A 500 ( 4.3A);D15 A 500 (-4.5A)","0.64A","5l2iA-4aguA:16.4","5l2iA-4aguA:35.54"],["5L2I_A_LQQA900_1","4at3","Homo sapiens","BDNF\/NT-3 GROWTH FACTORS RECEPTOR","PF07714(Pkinase_Tyr)",7,"GLY A 561;VAL A 568;ALA A 586;VAL A 617;PHE A 633;ASP A 640;LEU A 699","LTI A1839 ( 4.3A);None;LTI A1839 (-3.3A);None;LTI A1839 (-3.5A);None;LTI A1839 (-4.2A)","1.20A","5l2iA-4at3A:6.7","5l2iA-4at3A:27.38"],["5L2I_A_LQQA900_1","4aw2","Rattus norvegicus","SERINE\/THREONINE-PROTEIN KINASE MRCK ALPHA","PF00069(Pkinase);PF00433(Pkinase_C)",8,"GLY A  84;VAL A  91;ALA A 104;ASP A 161;THR A 164;LEU A 208;ALA A 218;ASP A 219","None;None;EDO A1420 (-3.4A);None;None;EDO A1420 ( 4.8A);None;None","0.74A","5l2iA-4aw2A:7.1","5l2iA-4aw2A:25.73"],["5L2I_A_LQQA900_1","4aw2","Rattus norvegicus","SERINE\/THREONINE-PROTEIN KINASE MRCK ALPHA","PF00069(Pkinase);PF00433(Pkinase_C)",7,"ILE A  83;GLY A  84;VAL A  91;ALA A 104;ASP A 161;THR A 164;LEU A 208","None;None;None;EDO A1420 (-3.4A);None;None;EDO A1420 ( 4.8A)","0.90A","5l2iA-4aw2A:7.1","5l2iA-4aw2A:25.73"],["5L2I_A_LQQA900_1","4bbm","Homo sapiens","CYCLIN-DEPENDENT KINASE-LIKE 2","PF00069(Pkinase)",6,"VAL A  18;ALA A  31;VAL A  64;PHE A  80;LEU A 133;ASP A 144","None;TC0 A 500 (-3.5A);TC0 A 500 (-4.7A);TC0 A 500 (-3.4A);TC0 A 500 (-4.3A);TC0 A 500 (-4.8A)","0.58A","5l2iA-4bbmA:13.2","5l2iA-4bbmA:33.62"],["5L2I_A_LQQA900_1","4bgq","Homo sapiens","CYCLIN-DEPENDENT KINASE-LIKE 5","PF00069(Pkinase)",7,"GLY A  20;TYR A  24;VAL A  27;ALA A  40;VAL A  73;PHE A  89;LEU A 142","None;38R A1000 (-3.6A);38R A1000 ( 4.8A);38R A1000 (-3.4A);None;38R A1000 ( 3.8A);38R A1000 ( 4.5A)","0.85A","5l2iA-4bgqA:16.7","5l2iA-4bgqA:35.76"],["5L2I_A_LQQA900_1","4crs","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE N2","PF00069(Pkinase);PF00433(Pkinase_C)",6,"VAL A 671;ALA A 684;VAL A 721;ASP A 744;LEU A 789;ALA A 799","AGS A1985 (-4.6A);AGS A1985 (-3.5A);None;AGS A1985 (-4.0A);AGS A1985 (-4.8A);AGS A1985 ( 4.5A)","0.45A","5l2iA-4crsA:8.0","5l2iA-4crsA:26.30"],["5L2I_A_LQQA900_1","4e93","Homo sapiens","TYROSINE-PROTEIN KINASE FES\/FPS","PF00017(SH2);PF07714(Pkinase_Tyr)",6,"ALA A 588;VAL A 620;ASP A 643;THR A 646;LEU A 690;ASP A 701","GUI A 901 (-3.4A);None;GUI A 901 ( 4.8A);GUI A 901 ( 3.8A);GUI A 901 (-4.3A);GUI A 901 ( 4.1A)","0.65A","5l2iA-4e93A:7.6","5l2iA-4e93A:22.06"],["5L2I_A_LQQA900_1","4e93","Homo sapiens","TYROSINE-PROTEIN KINASE FES\/FPS","PF00017(SH2);PF07714(Pkinase_Tyr)",8,"ILE A 567;GLY A 568;VAL A 575;ALA A 588;VAL A 620;ASP A 643;THR A 646;LEU A 690","GUI A 901 (-4.0A);GUI A 901 ( 4.3A);GUI A 901 (-4.5A);GUI A 901 (-3.4A);None;GUI A 901 ( 4.8A);GUI A 901 ( 3.8A);GUI A 901 (-4.3A)","1.03A","5l2iA-4e93A:7.6","5l2iA-4e93A:22.06"],["5L2I_A_LQQA900_1","4eut","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE TBK1","PF00069(Pkinase)",6,"GLY A  16;VAL A  23;ALA A  36;VAL A  68;THR A  96;ASP A 157","BX7 A 401 ( 3.7A);BX7 A 401 (-4.4A);BX7 A 401 (-3.4A);None;BX7 A 401 ( 4.7A);BX7 A 401 ( 3.7A)","0.74A","5l2iA-4eutA:20.4","5l2iA-4eutA:26.89"],["5L2I_A_LQQA900_1","4ez5","Homo sapiens","CYCLIN-DEPENDENT KINASE 6","PF00069(Pkinase)",9,"GLY A  20;VAL A  27;VAL A  77;PHE A  98;ASP A 104;THR A 106;LEU A 152;ALA A 162;ASP A 163","None;None;0RS A 900 (-4.4A);0RS A 900 (-4.5A);0RS A 900 (-4.2A);None;0RS A 900 (-4.3A);0RS A 900 (-3.6A);0RS A 900 (-3.6A)","1.32A","5l2iA-4ez5A:24.2","5l2iA-4ez5A:100.00"],["5L2I_A_LQQA900_1","4ez5","Homo sapiens","CYCLIN-DEPENDENT KINASE 6","PF00069(Pkinase)",11,"ILE A  19;GLY A  20;VAL A  27;ALA A  41;VAL A  77;PHE A  98;ASP A 104;THR A 107;LEU A 152;ALA A 162;ASP A 163","0RS A 900 (-4.1A);None;None;0RS A 900 ( 3.7A);0RS A 900 (-4.4A);0RS A 900 (-4.5A);0RS A 900 (-4.2A);0RS A 900 (-4.2A);0RS A 900 (-4.3A);0RS A 900 (-3.6A);0RS A 900 (-3.6A)","0.55A","5l2iA-4ez5A:24.2","5l2iA-4ez5A:100.00"],["5L2I_A_LQQA900_1","4f0i","Homo sapiens","HIGH AFFINITY NERVE GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",7,"GLY A 516;VAL A 523;ALA A 541;VAL A 572;PHE A 588;ASP A 595;LEU A 656","None","0.83A","5l2iA-4f0iA:6.5","5l2iA-4f0iA:27.86"],["5L2I_A_LQQA900_1","4fr4","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 32A","PF00069(Pkinase)",7,"ILE A  29;GLY A  30;VAL A  37;ALA A  50;VAL A  84;ASP A 107;LEU A 153","STU A 401 (-4.1A);STU A 401 (-3.3A);STU A 401 ( 4.9A);STU A 401 (-3.2A);None;STU A 401 (-3.3A);STU A 401 (-4.7A)","0.74A","5l2iA-4fr4A:6.9","5l2iA-4fr4A:24.49"],["5L2I_A_LQQA900_1","4hvi","Homo sapiens","TYROSINE-PROTEIN KINASE JAK3","PF07714(Pkinase_Tyr)",6,"GLY A 829;VAL A 836;ALA A 853;VAL A 884;LEU A 956;ALA A 966","19S A1201 (-3.7A);19S A1201 (-4.4A);19S A1201 (-3.3A);None;19S A1201 (-4.5A);19S A1201 ( 4.1A)","0.56A","5l2iA-4hviA:22.9","5l2iA-4hviA:26.22"],["5L2I_A_LQQA900_1","4otd","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE N1","PF00069(Pkinase);PF00433(Pkinase_C)",7,"GLY A 628;VAL A 635;ALA A 648;VAL A 685;ASP A 708;LEU A 753;ALA A 763","None","0.64A","5l2iA-4otdA:7.3","5l2iA-4otdA:27.42"],["5L2I_A_LQQA900_1","4otd","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE N1","PF00069(Pkinase);PF00433(Pkinase_C)",7,"VAL A 635;ALA A 648;VAL A 685;ASP A 708;LEU A 753;ALA A 763;ASP A 764","None","0.89A","5l2iA-4otdA:7.3","5l2iA-4otdA:27.42"],["5L2I_A_LQQA900_1","4q9z","Homo sapiens","HUMAN PROTEIN KINASE C THETA","PF00069(Pkinase);PF00433(Pkinase_C)",6,"GLY A 387;VAL A 394;ALA A 407;ASP A 465;LEU A 511;ALA A 521","PZW A 801 ( 3.8A);PZW A 801 (-4.6A);PZW A 801 (-3.5A);None;PZW A 801 (-4.8A);PZW A 801 ( 4.6A)","0.72A","5l2iA-4q9zA:7.4","5l2iA-4q9zA:28.77"],["5L2I_A_LQQA900_1","4qtb","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE 3","PF00069(Pkinase)",7,"ILE A  48;GLY A  49;TYR A  53;VAL A  56;ALA A  69;ASP A 128;LEU A 173","38Z A 418 ( 4.4A);None;38Z A 418 (-3.5A);None;38Z A 418 (-3.4A);EDO A 413 (-2.9A);38Z A 418 (-4.4A)","0.75A","5l2iA-4qtbA:14.0","5l2iA-4qtbA:34.06"],["5L2I_A_LQQA900_1","4rew","Homo sapiens","5'-AMP-ACTIVATED PROTEIN KINASE CATALYTIC SUBUNIT ALPHA-1","PF00069(Pkinase);PF16579(AdenylateSensor)",6,"GLY A  25;VAL A  32;ALA A  45;LEU A 148;ALA A 158;ASP A 159","STU A 601 (-3.5A);STU A 601 ( 4.8A);STU A 601 (-3.2A);STU A 601 (-4.2A);STU A 601 ( 3.8A);STU A 601 (-3.7A)","0.72A","5l2iA-4rewA:8.0","5l2iA-4rewA:20.93"],["5L2I_A_LQQA900_1","4rt7","Homo sapiens","RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3","PF07714(Pkinase_Tyr)",7,"GLY A 617;VAL A 624;ALA A 642;VAL A 675;PHE A 691;ASP A 698;LEU A 818","None;None;P30 A1001 (-3.4A);None;P30 A1001 (-3.7A);None;P30 A1001 (-4.6A)","0.51A","5l2iA-4rt7A:6.7","5l2iA-4rt7A:23.37"],["5L2I_A_LQQA900_1","4wbo","Bos taurus","RHODOPSIN KINASE","PF00069(Pkinase);PF00615(RGS)",6,"GLY A 194;VAL A 201;ALA A 214;VAL A 248;ASP A 271;LEU A 321","None;None;ANW A 601 (-3.4A);None;None;ANW A 601 (-4.9A)","0.67A","5l2iA-4wboA:22.2","5l2iA-4wboA:19.89"],["5L2I_A_LQQA900_1","4xuf","Homo sapiens","RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3","PF07714(Pkinase_Tyr)",7,"GLY A 617;VAL A 624;ALA A 642;VAL A 675;PHE A 691;ASP A 698;LEU A 818","None;P30 A1001 ( 4.8A);P30 A1001 (-3.5A);None;P30 A1001 ( 4.3A);None;P30 A1001 (-4.3A)","0.54A","5l2iA-4xufA:6.9","5l2iA-4xufA:28.74"],["5L2I_A_LQQA900_1","4yc6","Homo sapiens","CYCLIN-DEPENDENT KINASE 1","PF00069(Pkinase)",7,"GLY A  13;ALA A  31;VAL A  64;ASP A  86;LEU A 135;ALA A 145;ASP A 146","None","1.34A","5l2iA-4yc6A:14.6","5l2iA-4yc6A:45.60"],["5L2I_A_LQQA900_1","4yc6","Homo sapiens","CYCLIN-DEPENDENT KINASE 1","PF00069(Pkinase)",7,"VAL A  18;ALA A  31;VAL A  64;PHE A  80;ASP A  86;LEU A 135;ALA A 145","None","0.68A","5l2iA-4yc6A:14.6","5l2iA-4yc6A:45.60"],["5L2I_A_LQQA900_1","4yff","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE TNNI3K","PF07714(Pkinase_Tyr)",6,"GLY A 470;VAL A 477;ALA A 488;LEU A 595;ALA A 605;ASP A 606","4CV A 801 ( 3.9A);None;4CV A 801 (-3.5A);4CV A 801 (-4.4A);4CV A 801 ( 3.9A);4CV A 801 (-3.5A)","0.51A","5l2iA-4yffA:21.4","5l2iA-4yffA:26.33"],["5L2I_A_LQQA900_1","4yff","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE TNNI3K","PF07714(Pkinase_Tyr)",6,"ILE A 469;GLY A 470;VAL A 477;ALA A 488;LEU A 595;ALA A 605","4CV A 801 (-4.3A);4CV A 801 ( 3.9A);None;4CV A 801 (-3.5A);4CV A 801 (-4.4A);4CV A 801 ( 3.9A)","0.69A","5l2iA-4yffA:21.4","5l2iA-4yffA:26.33"],["5L2I_A_LQQA900_1","4yhj","Homo sapiens","G PROTEIN-COUPLED RECEPTOR KINASE 4","PF00069(Pkinase);PF00615(RGS)",6,"GLY A 194;VAL A 201;ALA A 214;VAL A 248;ASP A 271;LEU A 319","AN2 A 601 (-3.4A);AN2 A 601 (-4.0A);AN2 A 601 (-3.6A);None;None;None","0.71A","5l2iA-4yhjA:9.2","5l2iA-4yhjA:21.37"],["5L2I_A_LQQA900_1","4ylj","Homo sapiens","DUAL SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 1A","PF00069(Pkinase)",7,"ILE A 165;GLY A 166;VAL A 173;ALA A 186;VAL A 222;PHE A 238;LEU A 294","4E1 A 505 ( 4.6A);4E1 A 505 (-3.5A);4E1 A 505 (-4.5A);4E1 A 505 (-3.5A);None;4E1 A 505 (-4.2A);None","0.74A","5l2iA-4yljA:12.8","5l2iA-4yljA:29.18"],["5L2I_A_LQQA900_1","5ci7","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE ULK1","PF00069(Pkinase)",7,"GLY A  23;VAL A  30;ALA A  44;VAL A  76;ASP A  99;ALA A 164;ASP A 165","51W A 401 (-3.3A);51W A 401 ( 4.3A);51W A 401 (-3.4A);None;51W A 401 (-3.8A);None;GOL A 404 (-3.2A)","0.82A","5l2iA-5ci7A:8.1","5l2iA-5ci7A:29.23"],["5L2I_A_LQQA900_1","5ci7","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE ULK1","PF00069(Pkinase)",7,"GLY A  23;VAL A  30;ALA A  44;VAL A  76;ASP A  99;LEU A 145;ALA A 164","51W A 401 (-3.3A);51W A 401 ( 4.3A);51W A 401 (-3.4A);None;51W A 401 (-3.8A);51W A 401 (-4.5A);None","0.61A","5l2iA-5ci7A:8.1","5l2iA-5ci7A:29.23"],["5L2I_A_LQQA900_1","5dbx","Mus musculus","STE20\/SPS1-RELATED PROLINE-ALANINE-RICH PROTEIN KINASE","PF00069(Pkinase)",6,"ILE A  81;GLY A  82;VAL A  89;ALA A 102;VAL A 134;LEU A 211","ANP A 401 ( 4.1A);ANP A 401 ( 3.9A);ANP A 401 (-4.0A);ANP A 401 ( 4.0A);None;None","0.67A","5l2iA-5dbxA:5.2","5l2iA-5dbxA:27.27"],["5L2I_A_LQQA900_1","5es1","Homo sapiens","MAP\/MICROTUBULE AFFINITY-REGULATING KINASE 4","PF00069(Pkinase);PF00627(UBA)",6,"GLY A  63;VAL A  70;ALA A  83;VAL A 116;LEU A 185;ALA A 195","5RC A4000 ( 4.3A);5RC A4000 (-4.6A);5RC A4000 (-3.6A);None;None;5RC A4000 ( 3.9A)","0.65A","5l2iA-5es1A:8.0","5l2iA-5es1A:27.75"],["5L2I_A_LQQA900_1","5grn","Homo sapiens","PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA","PF07714(Pkinase_Tyr)",6,"GLY A 600;VAL A 607;ALA A 625;VAL A 658;ASP A 681;LEU A 825","None;748 A1001 ( 4.7A);748 A1001 (-3.7A);748 A1001 ( 4.8A);None;748 A1001 (-4.3A)","0.55A","5l2iA-5grnA:22.4","5l2iA-5grnA:26.86"],["5L2I_A_LQQA900_1","5gza","Danio rerio","PROTEIN O-MANNOSE KINASE","PF07714(Pkinase_Tyr)",6,"GLY A  86;VAL A  93;ALA A 104;VAL A 133;THR A 157;LEU A 214","ADP A 401 (-3.6A);ADP A 401 (-4.4A);ADP A 401 (-3.2A);None;None;ADP A 401 (-4.4A)","0.52A","5l2iA-5gzaA:15.7","5l2iA-5gzaA:23.24"],["5L2I_A_LQQA900_1","5hu3","Drosophila melanogaster","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE TYPE II ALPHA CHAIN","PF00069(Pkinase)",7,"GLY A  21;VAL A  28;ALA A  41;VAL A  74;PHE A  90;LEU A 143;ALA A 156","ADP A 301 (-3.6A);ADP A 301 (-3.7A);ADP A 301 (-3.5A);None;None;ADP A 301 (-4.7A);ADP A 301 ( 4.8A)","0.69A","5l2iA-5hu3A:7.9","5l2iA-5hu3A:31.56"],["5L2I_A_LQQA900_1","5idn","Homo sapiens","CYCLIN-DEPENDENT KINASE 8","PF00069(Pkinase)",6,"GLY A  28;VAL A  35;ALA A  50;ASP A 103;LEU A 158;ALA A 172","6A7 A 401 (-3.6A);6A7 A 401 ( 4.5A);6A7 A 401 (-3.3A);6A7 A 401 ( 4.9A);6A7 A 401 (-4.8A);6A7 A 401 ( 4.1A)","0.63A","5l2iA-5idnA:14.3","5l2iA-5idnA:32.80"],["5L2I_A_LQQA900_1","5idn","Homo sapiens","CYCLIN-DEPENDENT KINASE 8","PF00069(Pkinase)",6,"GLY A  28;VAL A  35;ALA A  50;PHE A  97;LEU A 158;ALA A 172","6A7 A 401 (-3.6A);6A7 A 401 ( 4.5A);6A7 A 401 (-3.3A);6A7 A 401 (-3.8A);6A7 A 401 (-4.8A);6A7 A 401 ( 4.1A)","0.68A","5l2iA-5idnA:14.3","5l2iA-5idnA:32.80"],["5L2I_A_LQQA900_1","5ig1","Salpingoeca rosetta","CAMK\/CAMK2 PROTEIN KINASE","PF00069(Pkinase)",7,"ILE A  24;GLY A  25;VAL A  32;ALA A  45;VAL A  78;PHE A  94;LEU A 147","None","0.84A","5l2iA-5ig1A:7.8","5l2iA-5ig1A:28.11"],["5L2I_A_LQQA900_1","5iso","Homo sapiens","5'-AMP-ACTIVATED PROTEIN KINASE CATALYTIC SUBUNIT ALPHA-2","PF00069(Pkinase);PF16579(AdenylateSensor)",6,"GLY A  23;VAL A  30;ALA A  43;LEU A 146;ALA A 156;ASP A 157","STU A 601 (-3.4A);STU A 601 (-4.8A);STU A 601 (-3.3A);STU A 601 (-4.5A);STU A 601 (-3.5A);STU A 601 (-3.5A)","0.60A","5l2iA-5isoA:7.8","5l2iA-5isoA:22.30"],["5L2I_A_LQQA900_1","5j5t","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 3","PF00069(Pkinase)",7,"GLY A  23;VAL A  30;ALA A  43;VAL A  74;LEU A 143;ALA A 153;ASP A 154","None;6G2 A 901 ( 4.9A);6G2 A 901 (-3.2A);None;6G2 A 901 (-4.7A);6G2 A 901 ( 4.2A);6G2 A 901 (-3.4A)","0.64A","5l2iA-5j5tA:20.9","5l2iA-5j5tA:26.77"],["5L2I_A_LQQA900_1","5jzn","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE DCLK1","PF00069(Pkinase)",6,"GLY A 397;VAL A 404;ALA A 417;VAL A 449;ASP A 472;LEU A 518","GUI A 701 ( 3.8A);GUI A 701 (-4.4A);GUI A 701 ( 3.9A);None;None;GUI A 701 (-4.4A)","0.63A","5l2iA-5jznA:7.9","5l2iA-5jznA:31.76"],["5L2I_A_LQQA900_1","5loh","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE GREATWALL,SERINE\/THREONINE-PROTEIN KINASE GREATWALL","PF00069(Pkinase)",6,"ILE A  41;VAL A  49;ALA A  60;VAL A  94;ASP A 117;LEU A 163","STU A 901 (-4.3A);None;STU A 901 (-3.3A);None;STU A 901 (-4.2A);STU A 901 (-4.5A)","0.59A","5l2iA-5lohA:8.3","5l2iA-5lohA:27.09"],["5L2I_A_LQQA900_1","5lxd","Homo sapiens","DUAL SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 2","PF00069(Pkinase)",6,"ILE A 155;GLY A 156;VAL A 163;ALA A 176;PHE A 228;LEU A 282","7A7 A 501 ( 4.3A);7A7 A 501 (-3.2A);7A7 A 501 (-4.4A);7A7 A 501 (-3.5A);7A7 A 501 (-3.7A);7A7 A 501 (-4.9A)","0.48A","5l2iA-5lxdA:16.1","5l2iA-5lxdA:26.18"],["5L2I_A_LQQA900_1","5myv","Homo sapiens","SRSF PROTEIN KINASE 2,SRSF PROTEIN KINASE 2","PF00069(Pkinase)",6,"GLY A  99;VAL A 106;ALA A 119;VAL A 157;PHE A 177;LEU A 232","W4A A 716 ( 4.0A);W4A A 716 ( 4.7A);W4A A 716 ( 3.9A);DMS A 717 (-4.3A);DMS A 717 ( 3.9A);None","0.74A","5l2iA-5myvA:14.6","5l2iA-5myvA:26.75"],["5L2I_A_LQQA900_1","5ncl","Saccharomyces cerevisiae","SERINE\/THREONINE-PROTEIN KINASE CBK1","no annotation",8,"ILE A 358;GLY A 359;VAL A 366;ALA A 379;VAL A 413;ASP A 436;THR A 439;LEU A 482","ANP A 801 (-4.2A);ANP A 801 ( 4.1A);ANP A 801 (-4.7A);ANP A 801 ( 3.9A);ANP A 801 ( 4.9A);ANP A 801 (-3.4A);None;ANP A 801 (-4.8A)","0.79A","5l2iA-5nclA:21.3","5l2iA-5nclA:16.60"],["5L2I_A_LQQA900_1","5u7q","Homo sapiens","RHO-ASSOCIATED PROTEIN KINASE 2","PF00069(Pkinase)",7,"GLY A  99;VAL A 106;ALA A 119;VAL A 153;ASP A 176;LEU A 221;ALA A 231","None","0.55A","5l2iA-5u7qA:7.6","5l2iA-5u7qA:26.05"],["5L2I_A_LQQA900_1","5xv7","Homo sapiens","SERINE-ARGININE (SR) PROTEIN KINASE 1","no annotation",7,"GLY A  87;VAL A  94;ALA A 107;VAL A 145;PHE A 165;LEU A 220;ALA A 496","EMH A 705 ( 3.9A);EMH A 705 ( 4.4A);EMH A 705 (-3.6A);EMH A 705 ( 4.9A);EMH A 705 (-3.6A);None;EMH A 705 ( 4.0A)","0.89A","5l2iA-5xv7A:10.9","5l2iA-5xv7A:14.53"],["5L2I_A_LQQA900_1","5y86","Homo sapiens","DUAL SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 3","no annotation",6,"GLY A 216;VAL A 223;ALA A 236;PHE A 288;ASP A 294;LEU A 342","None;HRM A 601 ( 4.9A);HRM A 601 (-3.5A);HRM A 601 (-3.6A);None;None","0.66A","5l2iA-5y86A:13.1","5l2iA-5y86A:13.07"],["5L2I_A_LQQA900_1","6b3e","Homo sapiens","CYCLIN-DEPENDENT KINASE 12","no annotation",9,"GLY A 734;VAL A 741;ALA A 754;VAL A 787;PHE A 813;ASP A 819;LEU A 866;ALA A 876;ASP A 877","CJM A1102 (-3.4A);None;CJM A1102 (-3.1A);None;CJM A1102 ( 4.4A);CJM A1102 (-4.1A);CJM A1102 (-4.4A);CJM A1102 (-3.6A); MG A1101 (-2.5A)","0.89A","5l2iA-6b3eA:13.1","5l2iA-6b3eA:16.06"],["5L2I_A_LQQA900_1","6b3e","Homo sapiens","CYCLIN-DEPENDENT KINASE 12","no annotation",7,"ILE A 733;GLY A 734;VAL A 741;ALA A 754;PHE A 813;ASP A 819;LEU A 866","CJM A1102 (-3.4A);CJM A1102 (-3.4A);None;CJM A1102 (-3.1A);CJM A1102 ( 4.4A);CJM A1102 (-4.1A);CJM A1102 (-4.4A)","0.74A","5l2iA-6b3eA:13.1","5l2iA-6b3eA:16.06"],["5L2I_A_LQQA900_1","6bql","Homo sapiens","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 2","no annotation",7,"GLY A 172;VAL A 179;ALA A 192;VAL A 249;PHE A 267;LEU A 319;ALA A 329","BI9 A 501 (-3.6A);BI9 A 501 ( 4.8A);BI9 A 501 (-3.3A);None;BI9 A 501 ( 4.2A);BI9 A 501 (-4.7A);NH4 A 506 ( 3.7A)","0.84A","5l2iA-6bqlA:8.0","5l2iA-6bqlA:13.64"],["5L2I_A_LQQA900_1","6c9d","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE MARK1,SERINE\/THREONINE-PROTEIN KINASE MARK1","no annotation",7,"ILE A  66;GLY A  67;VAL A  74;ALA A  87;VAL A 120;LEU A 189;ALA A 199","None","0.91A","5l2iA-6c9dA:7.8","5l2iA-6c9dA:12.99"],["5L2I_A_LQQA900_1","6ccf","Homo sapiens","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 1","no annotation",7,"GLY A 135;TYR A 139;VAL A 142;ALA A 155;VAL A 212;LEU A 282;ALA A 292","H1N A 501 ( 3.8A);None;H1N A 501 (-4.4A);H1N A 501 (-3.4A);H1N A 501 (-4.9A);H1N A 501 (-4.8A);H1N A 501 ( 3.9A)","0.70A","5l2iA-6ccfA:8.3","5l2iA-6ccfA:15.65"],["5L2I_A_LQQA900_1","6ccf","Homo sapiens","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 1","no annotation",7,"GLY A 135;VAL A 142;ALA A 155;VAL A 212;PHE A 230;LEU A 282;ALA A 292","H1N A 501 ( 3.8A);H1N A 501 (-4.4A);H1N A 501 (-3.4A);H1N A 501 (-4.9A);H1N A 501 (-3.7A);H1N A 501 (-4.8A);H1N A 501 ( 3.9A)","0.63A","5l2iA-6ccfA:8.3","5l2iA-6ccfA:15.65"],["5L2I_A_LQQA900_1","6cmj","Homo sapiens","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 2","no annotation",8,"GLY A 172;VAL A 179;ALA A 192;VAL A 249;PHE A 267;LEU A 319;ALA A 329;ASP A 330","F6J A 501 ( 3.9A);F6J A 501 (-4.6A);F6J A 501 (-3.4A);None;F6J A 501 (-3.7A);F6J A 501 (-4.5A);F6J A 501 ( 4.0A);F6J A 501 (-3.8A)","0.81A","5l2iA-6cmjA:22.4","5l2iA-6cmjA:11.76"],["5L2I_A_LQQA900_1","6fyo","Homo sapiens","DUAL SPECIFICITY PROTEIN KINASE CLK1","no annotation",6,"GLY A 168;VAL A 175;ALA A 189;VAL A 225;PHE A 241;LEU A 295","None;None;EAQ A 501 (-3.6A);None;EAQ A 501 (-3.5A);EAQ A 501 (-4.9A)","0.64A","5l2iA-6fyoA:9.9","5l2iA-6fyoA:undetectable"]]